NASDAQ:CYTO Altamira Therapeutics - CYTO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $2.96 -0.03 (-1.00%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.93▼$3.0550-Day Range$2.76▼$6.0652-Week Range$2.70▼$43.00Volume22,401 shsAverage Volume65,901 shsMarket Capitalization$2.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Altamira Therapeutics (NASDAQ:CYTO) StockAltamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.Read More Receive CYTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTO Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest UpdateJanuary 26, 2023 | nasdaq.comAltamira: NASAR Interim Analysis Shows Superior Efficacy Of Bentrio In Seasonal Allergic RhinitisFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 25, 2023 | seekingalpha.comCYTO Altamira Therapeutics Ltd.January 24, 2023 | markets.businessinsider.comDow Rises 80 Points; Altamira Therapeutics Shares PlungeJanuary 24, 2023 | finance.yahoo.comAltamira Therapeutics Provides Update on Clinical Trials with BentrioJanuary 10, 2023 | finance.yahoo.comAltamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26thDecember 20, 2022 | finanznachrichten.deAltamira Therapeutics Ltd: Altamira Therapeutics Provides Year-End 2022 Business UpdateFebruary 5, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 19, 2022 | finance.yahoo.comAltamira Therapeutics Provides Year-End 2022 Business UpdateDecember 2, 2022 | finance.yahoo.comAltamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in AustraliaDecember 1, 2022 | finanznachrichten.deAltamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update and First Half 2022 Financial ResultsNovember 30, 2022 | finance.yahoo.comAltamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance PharmaNovember 30, 2022 | finance.yahoo.comAltamira Therapeutics Provides Business Update and First Half 2022 Financial ResultsNovember 22, 2022 | finance.yahoo.comIn Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque StabilityNovember 10, 2022 | finance.yahoo.comAltamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid EventNovember 9, 2022 | finance.yahoo.comAltamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid RequirementNovember 8, 2022 | finance.yahoo.comData Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen ExposureOctober 26, 2022 | finanznachrichten.deAltamira Therapeutics Ltd: Altamira Therapeutics Announces Reverse Stock SplitOctober 24, 2022 | finance.yahoo.comAltamira Therapeutics Announces Reverse Stock SplitOctober 21, 2022 | finance.yahoo.comAltamira Therapeutics Announces Divestiture of Inner Ear Development AssetsOctober 21, 2022 | investorplace.comWhy Is Altamira Therapeutics (CYTO) Stock Up 70% Today?October 13, 2022 | finance.yahoo.comAltamira Therapeutics to Participate at RNA Leaders USA CongressOctober 3, 2022 | baystreet.caAltamira Inches Higher as Tests ContinueOctober 3, 2022 | finance.yahoo.comAltamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in AustraliaSeptember 27, 2022 | finance.yahoo.comAltamira Therapeutics Re-launches Bentrio in Europe for Allergic RhinitisSeptember 13, 2022 | finance.yahoo.comAltamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CYTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTO Company Calendar Today2/05/2023Next Earnings (Estimated)4/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYTO CUSIPN/A CIK1601936 Webwww.aurismedical.com Phone(441) 295-5950Fax41-61-201-1351Employees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.18 Sales & Book Value Annual Sales$70,000.00 Price / Sales31.71 Cash FlowN/A Price / Cash FlowN/A Book Value$18.75 per share Price / Book0.16Miscellaneous Outstanding Shares750,000Free Float651,000Market Cap$2.22 million OptionableOptionable Beta1.34 Key ExecutivesThomas MeyerChairman & Chief Executive OfficerCovadonga PañedaChief Operating OfficerMarcel GremaudChief Financial OfficerKey CompetitorsStatera BiopharmaNASDAQ:STABScopus BioPharmaNASDAQ:SCPSCalithera BiosciencesNASDAQ:CALAAllarity TherapeuticsNASDAQ:ALLRInMed PharmaceuticalsNASDAQ:INMView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 111,880 shares on 11/7/2022Ownership: 16.683%View All Institutional Transactions CYTO Stock - Frequently Asked Questions How have CYTO shares performed in 2023? Altamira Therapeutics' stock was trading at $4.85 at the start of the year. Since then, CYTO stock has decreased by 39.0% and is now trading at $2.96. View the best growth stocks for 2023 here. Are investors shorting Altamira Therapeutics? Altamira Therapeutics saw a decline in short interest in January. As of January 15th, there was short interest totaling 18,800 shares, a decline of 49.9% from the December 31st total of 37,500 shares. Based on an average daily volume of 123,800 shares, the short-interest ratio is presently 0.2 days. Approximately 1.7% of the company's shares are sold short. View Altamira Therapeutics' Short Interest. When is Altamira Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 11th 2023. View our CYTO earnings forecast. When did Altamira Therapeutics' stock split? Shares of Altamira Therapeutics reverse split on the morning of Tuesday, October 25th 2022. The 1-20 reverse split was announced on Tuesday, October 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Altamira Therapeutics' stock symbol? Altamira Therapeutics trades on the NASDAQ under the ticker symbol "CYTO." Who are Altamira Therapeutics' major shareholders? Altamira Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Altamira Therapeutics? Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Altamira Therapeutics' stock price today? One share of CYTO stock can currently be purchased for approximately $2.96. How much money does Altamira Therapeutics make? Altamira Therapeutics (NASDAQ:CYTO) has a market capitalization of $2.22 million and generates $70,000.00 in revenue each year. How can I contact Altamira Therapeutics? Altamira Therapeutics' mailing address is Bahnhofstrasse 21, Zug, Zug 6300. The official website for the company is www.aurismedical.com. The company can be reached via phone at (441) 295-5950, via email at investors@aurismedical.com, or via fax at 41-61-201-1351. This page (NASDAQ:CYTO) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.